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Background. Maternal rectovaginal colonization with group B Streptococcus (GBS) is the most common pathway for GBS dis-
ease in mother, fetus, and newborn. This article, the second in a series estimating the burden of GBS, aims to determine the preva-
lence and serotype distribution of GBS colonizing pregnant women worldwide.
Methods. We conducted systematic literature reviews (PubMed/Medline, Embase, Latin American and Caribbean Health 
Sciences Literature [LILACS], World Health Organization Library Information System [WHOLIS], and Scopus), organized Chinese 
language searches, and sought unpublished data from investigator groups. We applied broad inclusion criteria to maximize data 
inputs, particularly from low- and middle-income contexts, and then applied new meta-analyses to adjust for studies with less-sen-
sitive sampling and laboratory techniques. We undertook meta-analyses to derive pooled estimates of maternal GBS colonization 
prevalence at national and regional levels.
Results. The dataset regarding colonization included 390 articles, 85 countries, and a total of 299 924 pregnant women. Our 
adjusted estimate for maternal GBS colonization worldwide was 18% (95% confidence interval [CI], 17%–19%), with regional vari-
ation (11%–35%), and lower prevalence in Southern Asia (12.5% [95% CI, 10%–15%]) and Eastern Asia (11% [95% CI, 10%–12%]). 
Bacterial serotypes I–V account for 98% of identified colonizing GBS isolates worldwide. Serotype III, associated with invasive dis-
ease, accounts for 25% (95% CI, 23%–28%), but is less frequent in some South American and Asian countries. Serotypes VI–IX are 
more common in Asia.
Conclusions. GBS colonizes pregnant women worldwide, but prevalence and serotype distribution vary, even after adjusting 
for laboratory methods. Lower GBS maternal colonization prevalence, with less serotype III, may help to explain lower GBS disease 
incidence in regions such as Asia. High prevalence worldwide, and more serotype data, are relevant to prevention efforts.
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Group B Streptococcus (GBS; Streptococcus agalactiae) via 
maternal rectovaginal colonization, causes a spectrum of dis-
ease including maternal infection, stillbirth, and early- and 
late-onset sepsis in newborns, and may contribute to preterm 
delivery and hypoxic ischemic encephalopathy [1]. Thus, 
ascertaining the worldwide prevalence and serotype distri-
bution of GBS colonizing the rectovaginal tracts of pregnant 
women is critical [2–4].
There may be true differences in GBS maternal colonization 
prevalence, with variation reported by region [5], ethnicity, and 
socioeconomic status [6]. However, some of this variation may 
be due to methodological issues, such as time of GBS screening 
(during pregnancy or at delivery [7]), sampling site (in particu-
lar, whether rectal samples were performed [8–11]), and labo-
ratory culture techniques, notably use of selective enrichment 
broth [12]. There is no established international standard for 
sampling for maternal GBS colonization; however, the recom-
mendation by the Centers for Disease Control and Prevention 
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(CDC) [13] of rectovaginal swabs at 35–37 weeks’ gestation 
with selective enrichment broth is frequently referred to, but 
not always applied especially in low- and middle-income set-
tings. Reviews that do not take into account these sources of 
variation may be misleading, especially if the methods differ in 
certain regions, and may underestimate prevalence when meth-
ods are less sensitive, but may exclude large geographical areas 
if strict criteria are followed.
A recent review, based on studies using the recommended 
methods described above, estimated maternal GBS prevalence 
as 17.9% (95% confidence interval [CI], 16.2%–19.7%) world-
wide, ranging from 11.1% (95% CI, 6.8%–15.3%) in Southeast 
Asia to 22.4% in Africa (95% CI, 18.1%–26.7%) [5]. This review 
included 78 studies from 37 countries, with major gaps in some 
regions, notably Africa and Asia. By employing broader inclu-
sion criteria, we aimed to capture the largest possible geograph-
ical spread of data on prevalence of maternal GBS colonization, 
while also collecting variables related to specimen collection 
and processing to adjust for studies where less sensitive meth-
ods were used.
In addition to the prevalence of GBS colonization in preg-
nant women, serotype distribution, which has not previously 
been systematically reviewed, is also important, both in terms 
of associations with invasive disease and thus potential vaccine 
relevance. There are currently 10 GBS serotypes (Ia, Ib, II, III, 
IV, V, VI, VII, VIII, IX) identified, based on the immunologic 
reactivity of the GBS capsular polysaccharides [14]. Some sero-
types are associated with more virulent clones and thus a pro-
pensity to invasive GBS disease [2]. This particularly applies to 
serotype III, which is frequently associated with the hypervir-
ulent clonal complex (CC) 17, a common cause of late-onset 
GBS disease [15–21] and, in particular, of meningitis [22]. Two 
of the 3 maternal vaccines in development are serotype-spe-
cific [23, 24] and their coverage will depend on the circulating 
serotypes.
This paper is the second in an 11-article supplement estimat-
ing the burden of group B streptococcal disease in pregnant 
women, stillbirths, and infants, which is important in terms of 
public health policy, notably to inform vaccine development [1]. 
The supplement includes systematic reviews and meta-analyses 
on adverse outcomes associated with GBS around birth [25–
32] to provide input parameters for worldwide estimates [23]. 
Figure 1 shows the disease schema for GBS, and the important 
first step of maternal colonization, which is the focus of this 
article.
The objectives of this study were to:
Figure 1. Maternal group B Streptococcus (GBS) colonization in GBS disease schema, as described by Lawn et al [1]. Abbreviations: GBS, group B Streptococcus; NE, 
neonatal encephalopathy.
Downloaded from https://academic.oup.com/cid/article-abstract/65/suppl_2/S100/4589589
by guest
on 01 December 2017
S102 • CID 2017:65 (Suppl 2) • Russell et al
1. Undertake comprehensive and systematic literature reviews 
and meta-analyses of
a. maternal GBS colonization prevalence for countries, 
regions, and worldwide; and
b. serotype distribution of GBS in maternal colonization.
2. Assess the inclusion criteria for data estimating the burden 
of GBS in pregnancy for women, stillbirth, and infants, with 
and without additional adjustment for these criteria;
3. Evaluate the data gaps and make recommendations for future 
research.
METHODS
This article is part of a study entitled “Systematic estimates 
of the burden of GBS worldwide in pregnant women, still-
births and infants.” The protocol was approved by the Clinical 
Research Ethics Committee (reference number 11966) at the 
London School of Hygiene & Tropical Medicine and approved 
on 30 November 2016.
Definitions
GBS colonization was defined as isolation by culture of GBS 
from either the vagina (high or low), rectum, or perianal region 
at any time during pregnancy.
Search Strategy and Selection Criteria
We identified data by systematic review of the published lit-
erature and through development of an investigator group of 
clinicians, researchers, and relevant professional institutions 
worldwide. The reviews and meta-analyses are reported accord-
ing to international guidelines [1, 33, 34].
Our search of published literature, dated up to 30 January 
2017, included Medline, Embase, Scopus, Literature in the 
Health Sciences in Latin America and the Caribbean (LILACS), 
and the World Health Organization Library Information System 
(WHOLIS) using search terms relating to mothers, pregnancy, 
and streptococci, with no language or date restrictions (see 
Supplementary Table 1 for full search terms). To ensure inclu-
sion of data in languages that may otherwise be missed in these 
databases, we also searched a Chinese database (http://www.
cnki.com.cn/index.htm), with a time restriction of 3  years, 
and a Russian database (Cyberleninka), with no date restric-
tions. Abstraction of data from articles in foreign languages was 
done with translators and only automated if translators were 
unavailable.
Finally, we searched reference lists of all relevant articles 
published after 2005, and other publications and reviews [5], 
focused on regions (Europe [35], Latin America [36], and 
low-income contexts [37]), as well maternal GBS serotypes [38].
We screened titles and abstracts according to specified inclu-
sion and exclusion criteria, followed by selection of full texts, 
and abstraction, as detailed below.
Inclusion and Exclusion Criteria
We included studies where the population and study design 
were described, reporting prevalence of group B streptococcal 
colonization in pregnant women, either during pregnancy (at 
any gestation) or in labor, as well as on the prevalence of the 
serotypes of colonizing isolates. Studies were included irrespec-
tive of sample type (taken from the vagina [high or low] and/or 
rectum and/or perianal region) and culture technique, as long 
as laboratory and sampling techniques were described (for sub-
sequent sensitivity and secondary analyses). Although no date 
restrictions were applied to the initial search, for United Nations 
(UN)–defined “developed regions” (which were expected to 
have adequate recent data), data on maternal GBS colonization 
prevalence and on colonizing serotypes were only included in 
the analysis if published after the year 2000, unless a particular 
developed country only had data before this period.
We excluded studies involving nonpregnant women, where 
results for pregnant women could not be separately extracted. 
If prevalence estimates were based on <200 women sampled 
from that country, these were not included in the final esti-
mation process. We also did not derive prevalence estimates 
from studies in developed regions that focused solely on com-
parison of laboratory methods. Studies reporting prevalence of 
GBS colonization using molecular methods only for detection 
(such as polymerase chain reaction) or GBS bacteriuria alone 
were also excluded, due to their lack of comparability with con-
ventional methods, limiting cross-country and regional com-
parison. Data on serotypes were included if they were clearly 
identified as colonizing pregnant women vaginally or rectally, 
and were not from invasive disease. Data were included where 
they described a cohort of women, or pooled laboratory sam-
ples, and studies were excluded if they included <10 bacterial 
isolates.
Data Abstraction and Analysis
Two researchers (N. R. and M. O.) abstracted data independently 
into standard Excel abstraction forms with information on sam-
pling and laboratory methodology and relevant study criteria. 
Differences in abstraction were resolved through discussion 
with a third researcher (A. S.). Abstracted data included selec-
tion of study participants, description of study setting and par-
ticipants, culture methods, swab site, and timing of swabs (at 
delivery or at specified gestational ages). These factors allowed 
an assessment of the potential for bias in each study.
Maternal Group B Streptococcus Colonization Prevalence: Meta-analyses 
of Reported Data
We undertook meta-analyses using random effects to estimate 
the prevalence of maternal GBS colonization worldwide and at 
national, UN subregion, and regional levels, and used the same 
approach to estimate the prevalence of maternal GBS serotypes 
from national to regional levels worldwide.
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Sensitivity Analyses to Inform Adjustment for Biases
Sensitivity analyses were performed to assess potential biases in 
the data and inform adjustments. We examined:
1. Sample site collection comparing vaginal (high and low) 
sampling, with rectal sampling and rectovaginal sampling.
2. Microbiological methods (specifically, whether selective 
enrichment was used).
3. Sample timing (before 35 weeks’ gestation, or at delivery).
4. Rural or urban setting.
We calculated adjustment factors for:
1. Sample site: where only the vagina had been sampled (com-
pared to rectovaginal).
2. Microbiological methods: for the addition of selective enrich-
ment, compared to nonselective agar alone, and to conven-
tional selective agars (blood agars with antibiotics, including 
Columbia colistin–nalidixic acid [CNA] and neomycin–
nalidixic acid [NNA]. (Adjustment was not applied for new 
[higher sensitivity] selective agars of equivalent sensitivity to 
selective enrichment.)
However, where both sample site and microbiological meth-
ods were insensitive (sampling sites of high vagina or cervix, 
or rectal swab alone, and studies with combinations of low vag-
inal swabs but no selective enrichment), or adjustment was not 
possible due to insufficient data, we excluded studies from final 
estimates of maternal GBS prevalence. Adjustment factors were 
not calculated for sample timing or rural or urban setting as 
studies have not shown a consistent relationship between these 
factors and colonization prevalence [39–52].
Maternal Group B Streptococcus Colonization Prevalence: Meta-analyses 
With Adjusted Data
We repeated the initial meta-analyses to estimate the prevalence 
of maternal GBS colonization and serotype distribution world-
wide and by region, subregion, and country level using studies 
including vaginorectal samples with selective enrichment or 
with selective agar of equivalent sensitivity, and, after adjust-
ment, vaginal-only samples with selective enrichment or selec-
tive agar and vaginorectal samples with conventional selective 
agar only.
Meta-analyses of Maternal Group B Streptococcus Colonizing Serotypes
Data on serotypes were extracted as reported, as numbers of 
each serotype identified, with a denominator of number of 
serotyped samples rather than number of women. Individual 
meta-analyses were performed on the prevalence of each 
serotype at national, UN subregional, and regional levels, and 
the outputs of these meta-analyses were transformed into 
percentages.
RESULTS
Study Selection
We identified 8134 articles, 791 of which were retained after 
title and abstract screening for review of full texts (Figure 2). An 
additional 11 articles were identified from the Chinese database 
and 10 from searching reference lists of the original set of arti-
cles. A further 8 unpublished datasets containing anonymized 
data on 8601 pregnant women were shared by investigators in 
South Africa, Mozambique, Guatemala, India, and Bangladesh 
(Supplementary Table 2). The characteristics of the published 
and unpublished studies are listed in the Supplementary 
Materials. The majority of studies were in English, although 
70 studies were in 17 other languages. The process of selection 
is detailed in Figure 2. The final analysis included 390 studies 
(including 412 data points), of which 317 reported maternal 
GBS colonization prevalence, and 119 reported data on mater-
nal colonizing serotypes (52 included serotype data alone). 
Forty studies were included in sensitivity analyses to assess 
sampling site and microbiological methods (21 of which did not 
otherwise contribute to colonization or serotype data).
Study Characteristics
This review included data on colonization prevalence from 
299 924 pregnant women, with serotype data on 16 882 mater-
nal samples (16 181 of which were typeable by either molecular 
or conventional methods). Of studies reporting colonization 
prevalence, 31 (10%) described inclusion of rural participants. 
Eighty-two (26%) described testing for GBS colonization 
at delivery, and 94 (30%) described including samples from 
women tested before 35 weeks’ gestation. Selective culture 
methods were used in 249 studies (79%), and 215 studies (68%) 
used rectal as well as vaginal swabs (Supplementary Table 3).
There were 88 studies on colonization prevalence from devel-
oped regions (28%), and 229 from low- or middle-income con-
texts, 45 (19%) of which were published before the year 2000. 
The geographical distribution of available prevalence data was 
uneven (Figure 3), with some subregions underrepresented. In 
particular, there were no data from Central Asia, and data were 
sparse for Andean Latin America, Oceania, North Africa, and 
western and central sub-Saharan Africa (Figure 3). Of note, sev-
eral countries with large populations, such as Russia, had sur-
prisingly few data. A full list of countries included by region and 
country is in Supplementary Table 4.
For maternal colonizing serotypes, the geographical dis-
tribution is summarized in Figure  4, and shown in detail in 
Supplementary Table 5 and Supplementary Figure 1. Developed 
countries had the largest number of studies, followed by sub-Sa-
haran Africa where a number of large studies have recently been 
published [53, 54]. Northern Africa had the fewest serotyped 
isolates (58) of all regions with data. No serotype data were 
available for central Asia, Melanesia, or the Caribbean. Seven 
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studies (3 of which were from Central America) did not differ-
entiate between serotype Ia and Ib, and therefore a combined 
serotype I prevalence is reported in Figure 4, with a breakdown 
into Ia and Ib shown in Supplementary Table 5.
Maternal Group B Streptococcus Colonization Prevalence: Meta-analyses 
of Reported Data
Including all studies regardless of sample site or microbiologi-
cal methods and without adjustment, the overall prevalence of 
maternal GBS colonization worldwide was 15% (95% confi-
dence interval [CI], 14%–16%) (Table 1). Prevalence was high-
est in the Caribbean (34% [95% CI, 29%–38%]) and lowest in 
Melanesia (2% [95% CI, 1%–4%]); however, this included data 
from only 1 study. Europe, North America, and Australia had 
similar prevalence (95% CI, 15%–21%), with a slightly higher 
prevalence in Southern Africa (25% [95% CI, 22%–29%]), and 
seemingly lower prevalence in Western Africa (14%), Central 
Figure  2. Data search and included studies for maternal group B Streptococcus colonization. Abbreviations: LILACS, Latin American and Caribbean Health Sciences 
Literature; WHOLIS, World Health Organization Library Information System.
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America (10% [95% CI, 7%–14%]), and South, South-Eastern, 
and Eastern Asia (95% CI, 9%–12%). A list of maternal GBS col-
onization prevalence by country is presented in Supplementary 
Table 6.
Sensitivity Analyses to Inform Adjustment for Biases
Sensitivity analyses were performed on:
1. Sample site collection: studies using CDC-recommended 
sampling with rectovaginal swabs and selective enrichment 
(or selective agar of equivalent sensitivity):
Including only studies using CDC-recommended methods, we 
found 188 studies with a maternal GBS colonization prevalence 
of 17% (95% CI, 16%–19%), higher than the initial analysis 
with all the included studies. The prevalence for subregions and 
countries also changed because of geographic tendencies to use 
different methods (see Table  1 and Supplementary Materials, 
respectively). Some regions with low prevalence on crude anal-
ysis were excluded from this analysis, but some in some regions 
such as some Asian countries, the low prevalence persisted.
2. Sample timing (before and after 35 weeks’ gestation, or at 
delivery):
The overall prevalence of maternal GBS colonization in studies that 
reported samples from pregnant women before 35 weeks’ gestation 
was 17% (95% CI, 15%–18%), then 15% (95% CI, 13%–16%) in 
those sampled after 35 weeks, and 14% (95% CI, 13%–16%) at 
delivery.
Figure 3. Geographic distribution of included data, showing the range of number of women tested per country. Data for Algeria, Libya, Portugal, and Qatar were excluded 
from final analyses due to inadequate description of culture methods. Borders of countries/territories in the map do not imply any political statement. 
Figure 4. Maternal group B Streptococcus colonizing serotype distribution by United Nations subregion.
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3. Rural or urban settings:
In mixed urban/rural settings, the prevalence of maternal GBS 
colonization was 20% (95% CI, 17%–23%) (24 studies from 14 
subregions), and 21% (95% CI, 15%–27%) in exclusively rural 
settings (6 studies) (Supplementary Figures 2 and 3).
Adjustments to Address Biases
We calculated adjustment factors for sample site and microbio-
logical methods (Table 2):
• For sample site: comparing sampling vaginorectally vs vagi-
nally only, based on 27 studies, the increase in detection (risk 
ratio) was 1.4 (95% CI, 1.3–1.6) (Supplementary Table 7 and 
Supplementary Figure 4).
• For microbiological methods: comparing a conventional 
selective agar (blood agar with antibiotics: CNS [most com-
monly] or NNA) with and without enrichment (10 studies), 
the increase in detection (risk ratio) was 1.5 (95% CI, 1.3–
1.7) (Supplementary Table  8 and Supplementary Figure  5). 
Compared to an unselective agar (eg, sheep blood agar alone) 
with and without selective enrichment (13 studies), the rela-
tive increase in sensitivity with selective enrichment was 1.9 
(95% CI, 1.6–2.1) (Supplementary Table 9 and Figure 6).
Maternal Group B Streptococcus Colonization Prevalence: Meta-analyses 
With Adjusted Data
The overall prevalence of maternal GBS was 18% (95% CI, 
17%–19%) (Table 1 and Supplementary Figure 7). The adjusted 
prevalence of GBS colonization by country is shown in Figure 5 
(detailed in Supplementary Table  6). The Caribbean had the 
highest prevalence of colonization (35% [95% CI, 35%–40%]), 
and Southern Asia and Eastern Asia had the lowest prevalence of 
GBS colonization (13% and 11%, respectively) (Supplementary 
Figures 8–11). Within these subregions, the Republic of Korea 
(8% [95% CI, 7%–9%]), Myanmar (9% [95% CI, 7%–11%]), 
India (10% [95% CI, 7%–12%]), Bangladesh (11% [95% CI, 
4%–18%]), and China (11% [95% CI, 10%–13%]) had the 
lowest prevalence, with higher prevalence found in Iran (16% 
Table 1. Maternal Group B Streptococcus Colonization Prevalence Results From Meta-analyses With Reported Data and Meta-analyses With Adjusted 
Data
Region/ 
Subregions
No. of 
Countries
No. of 
Pregnant 
Women Tested
Reported 
Prevalence, %
95% Confidence 
Interval
Prevalence From 
Studies With 
Recommended 
Methods Onlya, %
95% Confidence 
Interval
Adjusted 
Prevalenceb, %
95% 
Confidence 
Interval
Developed regions 29 144 604 18.4 17.0–19.8 21 19.6–22.3 19.2 17.7–20.7
Australia and  
New Zealand
2 2369 23.3 18.8–27.8 23.3 18.8–27.8 23.3 18.8–27.8
North America 2 27 462 22.0 19.2–24.8 23.0 20.9–25.1 23.2 21.1–25.3
Northern Europe 7 6702 20.6 16.6–24.7 24.1 21.9–26.4 22.2 19.1–25.4
Eastern Europe 7 15 737 20.8 17.3–24.4 22.9 18.7–27.2 23.0 19.2–26.8
Southern Europe 5 42 870 15.4 12.2–18.7 16.7 14.7–18.6 17.6 14.5–20.8
Western Europe 6 49 464 15.2 13.1–17.3 18.3 16.0–20.7 19.5 13.9–25.1
Americas 13 20 507 18.3 15.8–20.7 19.6 16.7–22.5 20.9 18.1–23.7
South America 8 16 141 15.9 13.5–18.2 15.7 13.0–18.5 18.4 15.5–21.3
Central America 2 3229 10.2 6.7–13.8 15.7 13.3–18.0 17.1 13.2–21.0
Caribbean 3 1137 33.5 28.8–38.3 33.5 28.8–38.3 34.7 29.5–39.9
Asia 20 98 842 11.0 10.0–12.0 11.6 10.5–12.7 12.8 11.8–13.9
Western Asia 7 15 124 14.3 11.-16.6 14.5 11.7–17.4 14.7 12.1–17.4
Central Asia 0 … … … … … … …
Southern Asia 4 15 838 10.0 8.3–11.6 10.0 7.5–12.6 12.5 10.2–14.8
South-Eastern Asia 6 4591 12.0 9.3–14.7 14.4 9.5–19.2 14.4 11.5–17.4
Eastern Asia 3 63 289 9.2 7.6–10.8 9.1 8.2–10.0 11.1 9.9–12.4
Africa 19 36 130 18.2 16.1–20.4 20.7 17.6–23.7 21.3 18.5–24.2
Northern Africa 3 1923 20.0 15.8–24.3 20.5 15.5–25.4 22.9 17.9–28.0
Western Africa 6 4860 13.6 9.0–18.3 17.2 6.2–28.3 17.5 10.8–24.1
Middle Africa 3 2058 18.6 16.9–20.3 19.3 15.9–22.7 23.9 14.7–33.1
Eastern Africa 6 14 071 18.2 15.0–21.5 19.4 15.5–23.3 19.4 15.9–23.0
Southern Africa 1 13 218 25.3 22.1–28.5 29.5 27.4–31.5 28.9 26.6–31.2
Oceania 1 440 19.0 6.8–31.3 … … … …
Melanesia 1 440 2.0 0.6–3.5 … … … …
Overall 300 176 15.2 14.3–16.0 17.4 16.3–18.5 18.0 16.9–19.1
aRecommended methods refers to studies including both rectal (or perianal) and vaginal swabs, and with selective enrichment or a selective agar proven to provide equivalent sensitivity.
bAdjusted prevalence for sample site and microbiological methods.
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[95% CI, 12%–20%]), Japan (16% [95% CI, 12%–20%]), and 
Pakistan (20% [95% CI, 6%–34%]). Importantly, some the data 
in some countries and regions could not be adjusted for (eg, Fiji, 
Melanesia) due to inadequate methods in the studies.
Meta-analyses of Maternal Group B Streptococcus Colonizing Serotypes
Serotypes Ia, Ib, II, III, and V colonized the rectovaginal tracts 
of women in all regions, accounting for 98% of serotypes glob-
ally; however, variation existed in the reported prevalence of 
these serotypes and, perhaps most importantly, in the prevalence 
of serotype III. Compared to an overall serotype III prevalence 
of 25%, Central America (11% of colonized women [95% CI, 
7%–14%]) and South-Eastern Asia (12% [95% CI, 6%–18%]), as 
well as some South Asian countries including India (11% [95% 
CI, 0–23%]) and Bangladesh (11% [95% CI, 7%–15%]), had a 
lower reported prevalence of serotype III (Figure 4). In particu-
lar, if the region of South Asia is separated from Iran (included 
in the UN Southern Asia subregion), then it has a particularly 
low prevalence of serotype III (10.4%). Other regional differ-
ences included greater serotype V prevalence (along with lower 
serotype III prevalence) in Western Africa. Other serotypes (VI, 
VII, VIII, and IX) appear to be much more frequently reported 
in Southern, South-Eastern, and Eastern Asia (Supplementary 
Tables 10 and 11; Supplementary Figures 12–16). Together they 
account for 20% of serotypes in South-Eastern Asia, for example.
DISCUSSION
GBS colonizes pregnant women in all regions of the world in 
which studies have been conducted. The prevalence rates vary 
in different geographical regions, and a strength of our review is 
that we sought to account as much as possible for variation due 
to differences in sampling and methodology, to shed light on true 
epidemiological variation. The worldwide prevalence postadjust-
ment was estimated at 18% (95% CI, 17%–19%) whereas preva-
lence preadjustment was 15% (95% CI, 14%–16%). Some regions 
had very different prevalence estimates after adjustment, which 
demonstrates how prevalence may have been underestimated 
previously. The data in some countries were inadequate and 
could not be adjusted for, and their crude prevalences are likely 
to be significant underestimates of true prevalence. However, 
Table 2. Adjustment Factors to Address Biases
Addition or Inclusion
Comparison Method (of Lower 
Sensitivity) CDC-Recommended Method No. of Studies
Adjustment Factor 
(Factor Increase in 
Sensitivity) (95% CI)
Addition of rectal swabs to vaginal 
swabs (vaginal vs vaginorectal 
sampling)
Vaginal only Rectovaginal 27 1.4 (1.3–1.6)
Inclusion of selective enrichment 
broth to unselective agar
Blood agar alone without 
antibiotics
Agar + selective enrichment broth
- Todd Hewitt + gentamicin and nalidixic acid
- Todd-Hewitt + colistin and nalidixic acid
13 1.9 (1.6–2.1)
Inclusion of selective enrichment 
broth to a blood agar including 
antibiotics
Blood agar with antibiotics
- Columbia colistin–nalidixic acid
- Neomycin–nalidixic acid
Agar + selective enrichment broth
- Todd Hewitt + gentamicin and nalidixic acid
- Todd-Hewitt + colistin and nalidixic acid
10 1.5 (1.3–1.7)
Most common examples are shown. For more details and meta-analyses, see the Supplementary Materials.
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, confidence interval.
Figure 5. Prevalence of group B Streptococcus (GBS) colonization by country, adjusting for sampling site and laboratory culture method. Borders of countries/territories in 
map do not imply any political statement.
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considerable regional variation remained; in particular, Southern 
and Eastern Asian countries had a lower estimated prevalence of 
maternal GBS colonization. In addition, there were clear regional 
differences in colonizing serotypes. Notably, serotype III was less 
frequently found in Asia, with otherwise less common serotypes 
such as VI, VII, and VIII more frequently found. Within Africa, 
serotype V is more frequently reported in Western Africa than in 
other regions.
Differences in prevalence of GBS colonization and serotype 
distribution among mothers in different regions may help to 
explain apparent differences in incidence of newborn invasive 
GBS disease. Low apparent incidence of neonatal early-on-
set GBS disease in South Asia might, for example, be partly 
explained by a combination of lower overall prevalence of 
maternal GBS colonization and a lower prevalence of serotype 
III in those who are colonized. However, we need more data, 
particularly with sensitive methods, on maternal GBS coloniza-
tion prevalence and serotypes, particularly from the countries 
where there were limited or no data, and where colonization 
prevalence was very different to that found elsewhere (eg, 
Southern Asia, Melanesia, Central America, and Central Asia).
This is the largest systematic review and meta-analysis to date 
of published and unpublished data on maternal GBS colonization 
and serotype distribution globally and involved 299 924 pregnant 
women, with pooled estimates of maternal GBS colonization prev-
alence made for 82 countries, in comparison with 73 791 women 
and 37 countries included in the most recent previous review [5]. 
This is also the first global systematic review of serotypes coloniz-
ing pregnant women, including 16 181 bacterial isolates. However, 
there are limitations. The majority of studies with the most sensi-
tive sampling and microbiological techniques and the largest sam-
ple sizes came from high-income contexts. With the exception of 
a few recent reports [53, 54], studies from low-income contexts 
have frequently used less-sensitive sampling and microbiological 
methods, and have had small sample sizes and overrepresentation 
of urban referral hospitals. For many low-income contexts in par-
ticular, the data are thus potentially biased toward urban settings. 
Few studies directly compared urban and rural prevalence of GBS 
colonization, and these have shown conflicting results [49, 53, 55], 
as indeed have studies comparing primary and tertiary care [56] 
and high and low socioeconomic status [6, 53, 57–59]. Therefore, 
there may be variation, in different local contexts, in the extent 
and direction in which these factors influence maternal GBS colo-
nization prevalence. However, the reported variation may also be 
due to selection biases, especially for varying levels of care. In this 
review, although there were few direct comparisons, the overall 
maternal GBS colonization prevalence in rural contexts was com-
parable to urban contexts.
Other limitations include differences across studies in the 
timing of swabs. Screening later in pregnancy is more predic-
tive of GBS colonization during labor and therefore of the risk 
of neonatal invasive disease [44, 51, 60]. This review demon-
strated a marginally higher prevalence in studies with sam-
pling before 35 weeks (16.5% [95% CI, 14.9%–18.0%] vs 15.1% 
[95% CI, 13.8%–16.4%] after 35 weeks) which is supported by 
some longitudinal studies showing modest downward trends 
in prevalence during pregnancy, but contradicted by others 
[39–52, 61–64]. Current evidence suggests that overall pop-
ulation prevalence is relatively stable during pregnancy even 
if fluctuant at an individual level and that, for the purposes 
of population-level estimates of colonization, sampling preg-
nant women in the second trimester or third is unlikely to 
bias an overall estimate, even if swabs early in pregnancy are 
poor predictors of colonization at delivery.
We addressed some of the limitations in the data through 
adjustment where less-sensitive sampling or microbiological 
methods had been used and allowed inclusion of data from 
more low-income contexts. This assumed a consistent differ-
ence in sensitivity, which may not hold for all populations. 
A  single recent study in South Africa found that selective 
enrichment had lower sensitivity when used on rectal samples 
compared to direct plating onto selective agars [65], although 
the order of plating may have contributed to this. Overall, 
however, from our analyses (Supplementary Figures 1–3), 
Table 3. Key Findings and Implications
What’s new about this?
• This dataset covers 85 countries and includes 299 924 pregnant women, more than doubling the size of previous reviews, benefiting from translating 70 arti-
cles from 17 languages, and accessing unpublished data. In addition, we have undertaken meta-analyses showing consistently higher capture of GBS when 
sampling is rectovaginal (1.4 [95% CI, 1.3–1.6]) compared to vaginal only, or when selective enrichment is practiced (1.5 [95% CI, 1.3–1.7]). These findings 
allowed us to adjust input data, increasing comparability.
What was the main finding?
• We found a worldwide pooled estimate of 18% (95% CI, 17%–19%) for maternal GBS colonization prevalence, but with regional variation in prevalence (95% 
CI, 11%–35%), and also for serotype distribution.
How can the data be improved?
• Data gaps persist, as while 85 countries had useable data, more than half of 195 UN member states do not. Comparability would be improved by more stan-
dard sampling (rectovaginal swabs), laboratory methods (broth enrichment), and even newer more sensitive methods, with more reporting of serotypes and 
MLST types.
What does it mean for policy and programs?
• Our findings suggest that GBS is a common worldwide colonizer of pregnant women and that a GBS vaccine could be valuable in reducing the burden of 
GBS disease not just in high-income contexts.
Abbreviations: CI, confidence interval; GBS, group B Streptococcus; MLST, multilocus sequence typing; UN, United Nations.
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the increase in sensitivity when the most sensitive methods 
were used was consistent, and adjustment factors were tightly 
defined within 95% confidence intervals. Other factors that 
could affect the sensitivity of methods in different settings 
could not be accounted for, such as use of blood agar without 
specifying the source from which the blood was derived, which 
would lead to lower sensitivity if human blood, with or without 
ethylenediaminetetraacetic acid, were used instead of sheep 
blood, for example.
Our comprehensive review of GBS maternal colonization 
and serotype distribution highlights the important gaps in data 
that still exist. Future research on maternal GBS colonization 
should prioritize high-quality data from low-income con-
texts, especially rural populations and regions where there are 
large data gaps, such as South and Central Asia, Central and 
Western Africa, and Oceania. More phylogenetic data, includ-
ing sequence type clonal complex and serotype distributions, 
are also needed to understand the emergence and relationship 
between colonization and disease.
Despite data gaps, it is clear that GBS is present in all regions 
of the world as a pathogen colonizing pregnant women, and this 
finding has important implications for public health policy. The 
myths that GBS is only a pathogen in high-income contexts are 
no longer tenable. The associated burden would be amenable 
to prevention by intrapartum antibiotic prophylaxis or mater-
nal immunization. Improved data, including on serotypes, are 
important to guide effective decision making, and also monitor 
the impact of intervention (Table 3).
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